<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39314037</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-6576</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Acta anaesthesiologica Scandinavica</Title><ISOAbbreviation>Acta Anaesthesiol Scand</ISOAbbreviation></Journal><ArticleTitle>Prevalence and etiology of ventilator-associated pneumonia during the COVID-19 pandemic in Denmark: Wave-dependent lessons learned from a mixed-ICU.</ArticleTitle><Pagination><StartPage>1409</StartPage><EndPage>1416</EndPage><MedlinePgn>1409-1416</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/aas.14523</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Ventilator-associated pneumonia (VAP) may be a particular concern in patients with severe coronavirus disease 2019 (COVID-19). We aimed to determine the prevalence and etiology of VAP in critically ill COVID-19 patients in a Danish intensive care unit (ICU) during the first three waves of the COVID-19 pandemic and to study associations between dexamethasone (DXM) use and development of VAP.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In an observational single-center study patients were retrospectively screened for VAP including causative pathogens, use of DXM and commonly used antibiotics. Diagnosis of VAP required invasive mechanical ventilation (IMV) &gt;48 h with presence of a new bacterial agent and clinical signs of infection. For analysis, common descriptive statistics were applied. Cox proportional hazards models were used to analyze the association between DXM use and VAP.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">VAP was detected in 53/119 (44.5%) mechanically ventilated patients across all three COVID-19 waves. Median length of IMV for VAP patients was 24 [15-41] days, and 3 out of 4 were males. VAP was most prevalent (47.0%) during the second wave. Common pathogens included Klebsiella pneumoniae (24.5%), Enterobacter aerogenes (17.0%) and Pseudomonas aeruginosa (13.2%), Staphylococcus aureus (13.2%), and Escherichia coli (13.2%). A change from Gram-negative bacteria only to a combination of Gram-positive and Gram-negative bacteria was observed in the second wave compared to first. Use of DXM was not associated with VAP (adjusted hazard ratio 1.63 95% CI: 0.84-3.17).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The prevalence of VAP was high across all three COVID-19 waves and showed a different distribution of pathogens between the first and second wave. Use of DXM was not associated with VAP development. Further and larger studies are needed to understand the risk factors associated with VAP in patients with COVID-19.</AbstractText><CopyrightInformation>© 2024 Acta Anaesthesiologica Scandinavica Foundation.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Grzywacz</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><Identifier Source="ORCID">0009-0007-5583-4458</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care, Copenhagen University Hospital - Amager and Hvidovre Hospital, Hvidovre, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahlström</LastName><ForeName>Magnus G</ForeName><Initials>MG</Initials><Identifier Source="ORCID">0000-0001-5546-3959</Identifier><AffiliationInfo><Affiliation>Department of Clinical Microbiology, Copenhagen University Hospital - Amager and Hvidovre Hospital, Hvidovre, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benfield</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-0698-9385</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Copenhagen University Hospital -Amager and Hvidovre Hospital, Hvidovre, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berg</LastName><ForeName>Ronan M G</ForeName><Initials>RMG</Initials><Identifier Source="ORCID">0000-0002-5757-9506</Identifier><AffiliationInfo><Affiliation>Centre for Physical Activity Research (CFAS), Copenhagen University Hospital -Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital -Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plovsing</LastName><ForeName>Ronni R</ForeName><Initials>RR</Initials><Identifier Source="ORCID">0000-0002-6658-4833</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care, Copenhagen University Hospital - Amager and Hvidovre Hospital, Hvidovre, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ronit</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8960-7524</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Copenhagen University Hospital -Amager and Hvidovre Hospital, Hvidovre, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Acta Anaesthesiol Scand</MedlineTA><NlmUniqueID>0370270</NlmUniqueID><ISSNLinking>0001-5172</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>7S5I7G3JQL</RegistryNumber><NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053717" MajorTopicYN="Y">Pneumonia, Ventilator-Associated</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003718" MajorTopicYN="N" Type="Geographic">Denmark</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="Y">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="N">Respiration, Artificial</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003907" MajorTopicYN="N">Dexamethasone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID‐19</Keyword><Keyword MajorTopicYN="N">ICU</Keyword><Keyword MajorTopicYN="N">ventilator associated pneumonia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>2</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39314037</ArticleId><ArticleId IdType="doi">10.1111/aas.14523</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Statens Serum Institut. COVID‐19 smittetryk i de danske regioner (Accessed February 17, 2024). https://experience.arcgis.com/experience/220fef27d07d438889d651cc2e00076c/page/Covid‐19‐Regionalt/.</Citation></Reference><Reference><Citation>Danish Covid‐19 Genome Consortium. Genomic overview of SARS‐CoV‐2 in Denmark.</Citation></Reference><Reference><Citation>Haase N, Plovsing R, Christensen S, et al. Changes over time in characteristics, resource use and outcomes among ICU patients with COVID‐19—a nationwide, observational study in Denmark. Acta Anaesthesiol Scand. 2022;66(8):987‐995. doi:10.1111/aas.14113</Citation></Reference><Reference><Citation>Papazian L, Klompas M, Luyt CE. Ventilator‐associated pneumonia in adults: a narrative review. Intensive Care Med. 2020;46(5):888‐906. doi:10.1007/s00134‐020‐05980‐0</Citation></Reference><Reference><Citation>Spalding MC, Cripps MW, Minshall CT. Ventilator‐associated pneumonia: new definitions. Crit Care Clin. 2017;33(2):277‐292. doi:10.1016/j.ccc.2016.12.009</Citation></Reference><Reference><Citation>Fumagalli J, Panigada M, Klompas M, Berra L. Ventilator‐associated pneumonia among SARSCoV‐2 acute respiratory distress syndrome patients. Curr Opin Crit Care. 2022;28(1):74‐82. doi:10.1097/MCC.0000000000000908</Citation></Reference><Reference><Citation>Ippolito M, Misseri G, Catalisano G, et al. Ventilator‐associated pneumonia in patients with Covid‐19: a systematic review and meta‐analysis. Antibiotics. 2021;10(5):545. doi:10.3390/antibiotics10050545</Citation></Reference><Reference><Citation>Lamouche‐Wilquin P, Souchard J, Pere M, et al. Early steroids and ventilator‐associated pneumonia in COVID‐19‐related ARDS. Crit Care. 2022;26(1):233. doi:10.1186/s13054‐022‐04097‐8</Citation></Reference><Reference><Citation>Moreno J, Carvelli J, Lesaux A, et al. Ventilator acquired pneumonia in COVID‐19 ICU patients: a retrospective cohort study during Pandemia in France. J Clin Med. 2023;12(2):421. doi:10.3390/jcm12020421</Citation></Reference><Reference><Citation>Forsberg G, Taxbro K, Elander L, et al. Risk factors for ventilator‐associated lower respiratory tract infection in COVID‐19, a retrospective multicenter cohort study in Sweden. Acta Anaesthesiol Scand. 2023;1:226‐235. doi:10.1111/aas.14338</Citation></Reference><Reference><Citation>Maes M, Higginson E, Pereira‐Dias J, et al. Ventilator‐associated pneumonia in critically ill patients with COVID‐19. Crit Care. 2021;25(1):25. doi:10.1186/s13054‐021‐03460‐5</Citation></Reference><Reference><Citation>Wicky PH, Dupuis C, Cerf C, et al. Ventilator‐associated pneumonia in COVID‐19 patients admitted in intensive care units: relapse, therapeutic failure and attributable mortality—a multicentric observational study from the OutcomeRea network. J Clin Med. 2023;12(4):1298. doi:10.3390/jcm12041298</Citation></Reference><Reference><Citation>Velásquez‐Garcia L, Mejia‐Sanjuanelo A, Viasus D, Carratalà J. Causative agents of ventilator‐associated pneumonia and resistance to antibiotics in COVID‐19 patients: a systematic review. Biomedicine. 2022;10(6):1226. doi:10.3390/biomedicines10061226</Citation></Reference><Reference><Citation>Blonz G, Kouatchet A, Chudeau N, et al. Epidemiology and microbiology of ventilator‐associated pneumonia in COVID‐19 patients: a multicenter retrospective study in 188 patients in an un‐inundated French region. Crit Care. 2021;25(1):72. doi:10.1186/s13054‐021‐03493‐w</Citation></Reference><Reference><Citation>Ioanas M, Ferrer R, Angrill J, Ferrer M, Torres A. Microbial investigation in ventilator‐associated pneumonia. Eur Respir J. 2001;17:791‐801.</Citation></Reference><Reference><Citation>Langford BJ, So M, Raybardhan S, et al. Antibiotic prescribing in patients with COVID‐19: rapid review and meta‐analysis. Clin Microbiol Infect. 2021;27(4):520‐531. doi:10.1016/j.cmi.2020.12.018</Citation></Reference><Reference><Citation>The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid‐19. N Engl J Med. 2021;384(8):693‐704. doi:10.1056/NEJMoa2021436</Citation></Reference><Reference><Citation>Chalmers JD, Crichton ML, Goeminne PC, et al. Management of hospitalised adults with coronavirus disease 2019 (COVID‐19): a European Respiratory Society living guideline. Eur Respir J. 2021;57(4):2100048. doi:10.1183/13993003.00048‐2021</Citation></Reference><Reference><Citation>Gragueb‐Chatti I, Lopez A, Hamidi D, et al. Impact of dexamethasone on the incidence of ventilator‐associated pneumonia and blood stream infections in COVID‐19 patients requiring invasive mechanical ventilation: a multicenter retrospective study. Ann Intensive Care. 2021;11(1):87. doi:10.1186/s13613‐021‐00876‐8</Citation></Reference><Reference><Citation>Razazi K, Arrestier R, Haudebourg AF, et al. Risks of ventilator‐associated pneumonia and invasive pulmonary aspergillosis in patients with viral acute respiratory distress syndrome related or not to coronavirus 19 disease. Crit Care. 2020;24(1):699. doi:10.1186/s13054‐020‐03417‐0</Citation></Reference><Reference><Citation>Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of dexamethasone on days alive and ventilator‐free in patients with moderate or severe acute respiratory distress syndrome and COVID‐19: the CoDEX randomized clinical trial. J Am Med Assoc. 2020;324(13):1307‐1316. doi:10.1001/jama.2020.17021</Citation></Reference><Reference><Citation>Meier N, Perner A, Plovsing R, et al. Long‐term outcomes in COVID‐19 patients admitted to intensive care in Denmark: a nationwide observational study. Acta Anaesthesiol Scand. 2023;67(9):1239‐1248. doi:10.1111/aas.14290</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>